Jessica Huston,Hannah Schaffner,Logan Langley et al.
Jessica Huston et al.
Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels. When blood glucose levels are inadequately controlled or left untreated, the result is a variety of microvascular and macrovascular complica...
Lucio Manenti,Paride Fenaroli
Lucio Manenti
Chronic kidney disease-associated pruritus (CKD-aP) has been recognized for over a century. The complex pathophysiology of CKD-aP makes it challenging to find an effective treatment; the proposed therapeutic options come from anecdotal repo...
Melphalan flufenamide for relapsed/refractory multiple myeloma [0.03%]
复发/难治多发性骨髓瘤患者中位生存期超1年新型药物MMAYS研究结果公布
Omar Nadeem,Maria-Victoria Mateos,Yvonne A Efebera et al.
Omar Nadeem et al.
Despite therapeutic advances and improved patient outcomes in recent years, multiple myeloma (MM) remains a mostly incurable hematologic malignancy. Patients with relapsed/refractory MM (RRMM), especially those with triple-class-refractory ...
Kate Bedrin,Jessica Ailani
Kate Bedrin
Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regula...
Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer [0.03%]
安维汀：非小细胞肺癌表皮生长因子受体第20号外显子插入突变的单克隆EGFR-MET双特异性抗体治疗药物
Yuhao Xie,Qisi Lu,Jing-Quan Wang et al.
Yuhao Xie et al.
The U.S. Food and Drug Administration (FDA) first approved amivantamab, a monoclonal epidermal growth factor receptor (EGFR)-mesenchymal--epithelial transition factor (MET) bispecific antibody, in May 2021, to treat adult patients with loca...
Abrocitinib in atopic dermatitis: review of the current literature and clinical trials [0.03%]
阿布司替尼治疗特应性皮炎：文献和临床研究综述
Maddalena Napolitano,Luigi Fornaro,Luca Potestio et al.
Maddalena Napolitano et al.
Atopic dermatitis (AD) is an inflammatory chronic-relapsing skin disease affecting approximately 15% to 20% of children and 10% of adults in industrialized countries. Both loss of epidermal barrier permeability and immune dysregulation seem...
Elisabetta K Antonelli,Rachele Del Sordo,Olivia Morelli et al.
Elisabetta K Antonelli et al.
Treating moderate to severe ulcerative colitis (UC) has been enriched by the increasing number of drugs available for this disease. However, failure of conventional therapies, an incomplete response, or loss of response to biologics is expe...
Bela G Santani,Brian W LeBlanc,Ritesh P Thakare
Bela G Santani
Molnupiravir (MK-4482, EIDD-2801) is a promising broad-spectrum experimental antiviral developed by Merck & Co. It is a nucleoside analogue prodrug that undergoes rapid conversion into nucleoside triphosphate (NTP) by intracellular metaboli...
Saeed Sadeghi
Saeed Sadeghi
Cholangiocarcinoma (CCA) is a serious and often fatal cancer of the bile ducts of the liver with a 5-year survival rate of 5-15%. At the time of diagnosis, most patients present with advanced or metastatic CCA, which is an aggressive malign...
Grace Kaul,Arunava Dasgupta,Sidharth Chopra
Grace Kaul
Contezolid (MRX-I, Youxitai) is an oral oxazolidinone drug being developed by MicuRx Pharmaceutical Co., Ltd., Shanghai, China. It was approved by China's National Medical Products Administration (NMPA) in June 2021, attaining its first app...